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In Ghana, initiation of Antiretroviral Therapy (ART) is recommended for all patients with an
HIV diagnosis, regardless of CD4+ T-cell count. However, measurement of CD4 count
remains an important metric for identifying patients with advanced HIV disease, and assess-
ing a person’s overall immune status, which informs the decision to offer opportunistic infec-
tion screening and prophylaxis. Access to CD4+ T cell count in rural health facilities remains
a major challenge in Ghana and other resource-limited settings. This study aimed to validate
the accuracy of the BD FACSPresto near-patient device for measurement of CD4 count and
hemoglobin concentration against the FACSCount (CD4) and Sysmex (hemoglobin) diag-
nostic machines when operated in both a district hospital and rural laboratory, serving a net-
work of health posts in Ashanti Region, Ghana.
Methodology
In the first phase of the study, patients were recruited from a district hospital, and both
venous and capillary blood samples were tested using the FACSCount and Sysmex as ref-
erence tests and compared to results of the FACSPresto performed in the clinic laboratory
at the district hospital. In the second phase, patients were recruited from both the hospital
and from rural health clinics, and samples were tested using the FACSPresto at a rural labo-
ratory. Sensitivity and specificity among samples categorized into different clinically relevant
CD4 count ranges were calculated, along with correlation between the Presto and the refer-
ence measurements, and mean and relative bias with limits of agreement.
Results
The FACSPresto was successfully operated in both clinical settings. A total of 59 samples in
the first phase and 48 samples in the second phase were included. Positive bias was
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observed when comparing CD4 count measured by BD FACSPresto to FACSCount in the
district hospital (bias = 44, LOA -72,160) and in the rural laboratory setting (bias = 74, LOA
-96, 244). In addition, capillary blood samples were shown to give higher measures when
compared to venous blood samples from the same participant. All results were statistically
significant (p<0.05) apart from hemoglobin measurement in venous blood in the rural labora-
tory. Correlation coefficients were high for CD4 count measures and lower for hemoglobin
measures.
Conclusion
Overall, the Presto gave higher estimates of CD4 count compared to FACSCount, and
hemoglobin measurements were higher than from Sysmex. Samples of capillary blood in
turn gave higher results for both measurements compared to venous blood, consistent with
previous analyses. These findings should be considered when selecting CD4 count
machines for use at the point of care, especially in remote areas where capillary blood sam-
pling may be preferable, but are likely balanced by device’s ease of use, portability, and abil-
ity to expand access to services. These results are some of the first to demonstrate the
accuracy of the FACSPresto in West Africa and show that this device can be successfully
operated in a very rural lab setting and may therefore assist to provide CD4 count and hemo-
globin concentration measurement to populations in need.
Introduction
Proper clinical management of people living with HIV (PLHIV) requires access to laboratory
testing, including CD4 enumeration, liver and renal function tests and viral load (VL) moni-
toring. Since 2015, the World Health Organization (WHO) has recommended that antiretrovi-
ral treatment (ART) be initiated as soon as possible after diagnosis with HIV, regardless of
CD4 count[1], and if viral load testing is available, CD4 is no longer needed for long-term
monitoring for stable patients [2]. However, despite this “treat all” recommendation, CD4 test-
ing remains important for establishing baseline immune function and identifying patients
with advanced HIV disease (defined as CD4 T-cell count below 200 cells/μl), who are at higher
risk for opportunistic infections (OIs) [1, 3]. In addition, CD4 count can be an important indi-
cator of treatment failure [2]. Patients who are unstable or have advanced disease should
receive a package of services, including screening and prophylactic treatment for certain OIs,
or may need to be referred to specialized care. Therefore, it remains important that PLHIV on
ART, especially those beginning ART for the first time or after a treatment gap, have access to
CD4 enumeration.
Access to advanced diagnostic equipment for CD4 and viral load testing can be limited in
rural or remote communities, and patients may need to travel long distances for testing. Point-
of-care (POC) diagnostic tests, which are those used at or near the patient and outside of a lab-
oratory, can greatly increase access to services when lab capacity is limited. POC testing for
HIV infection has been widely adopted, and POC CD4 count testing shows potential for
improving disease management in many settings. A 2016 systematic review found that POC
CD4 testing is generally acceptable and feasible in low and middle income countries, and over-
all, prompt CD4 count testing upon diagnosis with HIV has been shown to improve rates of
linkage to care, and initiation of ART [4, 5]. Therefore, POC testing can facilitate access to
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services and higher quality of care, in both rural and urban areas. Introducing well-validated
devices for HIV diagnosis and monitoring is crucial to ensuring that all PLHIV have appropri-
ate care, and given the number of CD4 measurement devices on the market, device-specific
studies are needed to inform the selection of technologies for different settings [6].
There are numerous CD4 testing machines on the market, which vary greatly in sample
throughput and size, ranging from high-volume devices such as the BD FACSCalibur and
FACSCount, to smaller devices such as the CyFlow Mini POC (Sysmex), Pima (Abbott), and
CD4NOW (PointCare), which also provides hematology. Wide ranges of bias have been
reported across devices, highlighting the importance of using the same technology for longitu-
dinal patient monitoring whenever possible [7]. For the purpose of regulatory approvals, the
Presto has been validated against the FACSCalibur as reference standard for CD4 enumeration
[8–10], but FACSCount is also widely used, with instruments reported in 48 countries and
accounting for 31.6% of total reported CD4 instruments in a 2013 survey of WHO member
states [11]. In comparison, FACSCalibur was reported in 33 countries, and 12.5% of total CD4
instruments [11].
The BD FACSPresto (Becton Dickinson, San Jose, CA, USA)—referred to here as Presto—
is a portable, near-patient device which weighs less than 7 kg and able to be run using battery-
power [12, 13]. The device was released in 2014 and provides absolute CD4 count, percentage
of CD4 T-cells out of total lymphocytes, and hemoglobin (Hgb) concentration in a single test,
with a total test time of approximately 25 minutes. Hgb concentration is a measurement of
anemia, which is particularly relevant for pregnant women attending antenatal care (ANC).
Therefore, having on-site, quick access to CD4 enumeration and Hgb measurement in one test
could be important for prevention of mother to child transmission (PMTCT) of HIV pro-
grams. It has received regulatory approval by the US-FDA, the European Union (CE-IVD)
and the WHO Prequalification (PQ) Programme, among others, in which its performance was
compared to FACSCalibur [12, 14].
The Presto has been primarily studied in sub-Saharan Africa [8, 14–21] and is designed for
use in low-resource settings [13]. It has been validated previously against the BD FACSCalibur
and BD FACSCount in several countries in Eastern and Southern Africa, predominantly in
urban reference laboratory or hospital settings, with limited data on performance in rural set-
tings. Its diagnostic accuracy was assessed in a district hospital, an advanced laboratory (Kenya
Medical Research Institute/CDC) and in a community level facility in Kenya [8, 19, 21]; at an
urban HIV clinic in Johannesburg, South Africa [22], at a hospital-affiliated HIV clinic in
Harare, Zimbabwe [20], at a secondary hospital in Nigeria [23] and at four urban facilities in
Ethiopia [16]; additionally, a multi-site evaluation took place in hospitals in Kenya, Thailand,
San Francisco, and India [14], as well as in reference laboratories in Belgium and Tanzania
[15]. Seven out of ten studies reviewed found that Presto over-estimated CD4 count when
compared to the reference standard (FACSCount or FACSCalibur). Mean biases ranged from
-13.3 cells/μl [16] to +77.16 cells/μl [19]. In addition, all studies comparing venous samples to
capillary samples found that capillary samples give a systematically higher estimation of abso-
lute and/or relative CD4 count. Most studies were performed when CD4 count was used to
determine ART eligibility, and concluded that the Presto was accurate enough for this applica-
tion. This study took place before the 2015 “treat all” recommendation was implemented in
Ghana, and CD4 count cutoffs were still a critical factor for ART initiation. While all patients
are now eligible to begin ART regardless of CD4 count, CD4 remains an important indicator
of immune function and access to CD4 testing is still a priority for HIV control programs
worldwide.
The aim of this study was to evaluate the accuracy of the Presto in comparison to the BD
FACSCount (CD4 Count) and to the Sysmex KX– 21N (hemoglobin concentration) when the
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Presto was operated in a district hospital and at a rural laboratory in Ghana. To our knowl-
edge, this is the first study of the diagnostic accuracy of Presto in Ghana, one of few in West




This diagnostic accuracy study was conducted in two phases in Amansie West, Ashanti
Region, Ghana. Phase 1 took place from June to August 2015 at St. Martins District Hospital
(DH) in Agroyesum (the only hospital serving Amansie West district), and phase 2 from Feb-
ruary to August 2016, in which the Presto was operated in a small rural laboratory in Tontok-
rom village. Amansie West is one of Ashanti region’s 27 districts and in 2010, had a
population of 134,331, 95.5% of whom live in rural areas, and 74.1% subsist off agriculture
[24]. The rural laboratory provides basic diagnostic services and serves as a research center.
Typical of this level of health care facility, the lab suffers from occasional power outages, water
shortages, and limited staff.
At the time of this study, Ghana’s National Guidelines (2010) recommended ART initiation
for all PLHIV with CD4 counts less than 300, and for all pregnant women after 14 weeks gesta-
tion, regardless of CD4 count. At the same time, WHO recommended ART initiation for
PLHIV with CD4 counts of 350 cells/μl or below [25, 26]. Ashanti region had an HIV preva-
lence of 1.9% in 2014, compared to 2% national prevalence [27]. Ghana formally recom-
mended “treat all” irrespective of CD4 count in October of 2016 (shortly after the conclusion
of this study in August of 2016), but Option B+, which recommended lifelong ART for all
pregnant women regardless of CD4 count, had not yet been adopted in the region during this
study [12, 28].
Study design
This was a diagnostic accuracy study, separated into two phases, and distinguished by the loca-
tion of the Presto device either in the district hospital DH (phase 1) or the rural lab (phase 2).
In the first phase, all participants were recruited from the DH clinic, and samples were tested
on-site. Results from the Presto were compared to the FACSCount (Becton Dickinson, CA,
USA) for CD4 Count, and to the Sysmex KX– 21N (Sysmex Corporation, Japan) for hemoglo-
bin, which were also operated at the DH. In the second phase, the Presto was operated in the
rural laboratory, and results were compared again to the FACSCount and Sysmex, which were
still operated at the DH. Participants in phase 2 were recruited from rural clinics, as well as
from the DH. Samples from the DH were therefore transported to the rural laboratory for test-
ing on the Presto. Using Presto at the rural laboratory provided insight into the feasibility of
using near-patient CD4 counters in low-resource areas, as compared to the larger and better
equipped laboratory at the DH. The Presto test results were never used for patient care in
either phase, and all clinical decisions were made based on results from venous blood samples
tested on the reference machines.
Sample collection and testing
Training in the operation of the device, sample collection and basic trouble-shooting, was pro-
vided to all participating phlebotomists and technologists by the manufacturer through a one-
day training course. During the study, each sample was run on a total of 3 devices: the experi-
mental Presto (for CD4 and hemoglobin), the FACSCount as control for CD4, and the Sysmex
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as control for Hgb concentration. In phase 1, a capillary blood sample (applied using a lancet
to the test cartridge) and a 5 ml aliquot of venous blood from each patient were tested using
Presto and the reference machines at the DH HIV clinic. Samples were run on the Presto
machine within 30 minutes. All control hemoglobin analyses were performed on the Sysmex
on the same day, within a few hours of collection, but control CD4 count analyses were some-
times performed in batches, meaning some samples were stored overnight according to manu-
facturer’s recommendations and tested the day after collection on the FACSCount.
In phase 2, venous blood was collected at the DH and kept in cold chain at ~8˚C, before
being transported to the rural laboratory in test tubes by motorbike for testing by Presto the
same day. The laboratory is approximately one hour away by motorbike and all samples were
tested within 4–5 hours. A second aliquot of blood was tested at the DH on the reference
devices (FACSCount and Sysmex). Venous and capillary blood were also both collected from
patients at the rural lab, and an aliquot of venous blood was separated into a separate tube and
transported by motorbike to the DH laboratory for testing using the control devices; capillary
blood was never transported.
Study population
Adults (� 18 years old) from two groups were invited to participate: one group of patients at
the DH who came for HIV management and required a CD4 test, and a second group of peo-
ple from one of the community-level health clinics surrounding rural lab and also required a
test. Since chronic HIV care was not yet offered at the majority of community-level clinics
(only two out of ten nearby clinics offer ART), only ten participants were recruited from the
lower-tier health care facilities. Only participants 18 years or older who gave written consent
were included. Subjects included pregnant women but excluded children under 18.
Sample size
The aim was to collect samples from 100 participants (50 in each phase), but all eligible
patients were invited to enroll during the designated study period; 65 patients were recruited
to phase 1 and 53 to phase 2. This was a convenience sample and all participants were enrolled
consecutively. The sample size was limited by time constraints of the study, and based on nor-
mal volume at the district hospital. In phase 2, most participants were recruited from the dis-
trict hospital, with only ten eligible patients identified and included from the rural health
posts; due to low attendance for HIV care at rural clinics at the time. The Clinical and Labora-
tory Standards Institute (CLSI) recommends at least 40 samples of appropriate range (reflect-
ing both clinical range and analytical range of each method) when conducting accuracy
studies [29]; similar studies have used this benchmark to inform decisions on sample size [14,
19].
Ethics, safety, and informed consent
Eligible participants were informed about the purpose, benefits, and risks of the study, and
could ask questions. They gave written consent by circling “Yes” or “No”. When patients were
illiterate, the consent form (available in English and Twi) was read aloud. Ethical approval was
received from the Institutional Review Board (IRB) at Columbia University (IRB-AAAM4706)
and the Ghana Health Service Ethical Review Committee (GHSERC) for both phase 1 and
phase 2. Approval from the Ghana Food and Drug Authority (FDA) was obtained for using
Presto in Ghana.
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Statistical analyses
Descriptive statistics and measures of association between Presto and the reference methods
were calculated using Microsoft Excel, GraphPad Prism, and SAS version 3.5. Two sample T-
tests were used to compare mean age of male and female participants, and Wilcoxon Rank
Sum tests were used to compare CD4 count between males and females. Three different clini-
cally-relevant cutoff thresholds of CD4+ T Cell count were used: 100 to define the cut-off for
use of recommended screening tests for opportunistic infections (OIs) (i.e. TB-LAM and cryp-
tococcal antigen lateral flow assay) in patients with advanced HIV disease; and 350 and 500
cells/μl to reflect past ART initiation recommendations. Rates of upward, downward, and total
misclassification, along with sensitivity and specificity for specific cutoffs were calculated to
compare performance of the Presto to that of the FACSCount or Sysmex. Wilcoxon Signed
Rank tests and Spearman correlation were then used to compare results between methods,
using a significance level of 0.05. Bland Altman plots were produced to visualize bias and limits
of agreement (LOA) when comparing Presto to FACSCount. Only data from samples which
have pair-wise results available was included.
Results
Participant characteristics
65 patients consented to participate in phase 1, and paired results (Presto and control) from 59
venous samples and 57 capillary blood samples were obtained (Fig 1). In phase 2, 40 patients at
the DH consented to participate and venous blood samples from the DH were transported to
the rural laboratory, but 2 of these were excluded due to invalid results on Presto. An addi-
tional 13 patients from nearby community clinics provided venous and capillary blood sam-
ples. Three of the capillary samples were unusable, and control results were unavailable for 3
of the venous samples, resulting in a total of 38 venous samples from the DH and 10 paired
venous and capillary samples from the local clinics, representing a total of 48 participants in
phase 2. All 48 were tested at the rural laboratory.
Fig 1. Study recruitment for phase 1 and 2. Participants were recruited sequentially from both the district hospital (DH) and the rural laboratory. In phase 1,
all samples were analyzed in the DH from DH patients, and in phase 2, samples came from both DH and rural laboratory patients and all were analyzed in the
rural laboratory.
https://doi.org/10.1371/journal.pone.0212684.g001
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The majority (87.3%) of phase 1 study participants were female, with an average age of 40.3
years, of whom 4 were pregnant (Table 1). Men were older than women, with an average age
of 53 compared to 40 years (t = 3.55, p<0.001). In phase 2, the majority of participants were
again female (62.5%), and the mean age was 41.6 years. Ages were not significantly different
between men and women (t = 0.726, p = 0.47). Across both phases, participants were relatively
healthy, with only 3.4% (phase 1) and 4.2% (phase 2) of patients with CD4 counts of under 100
cells/μl (according to the FACSCount reference test, Table 2). The majority of participants
(61% in phase 1 and 56% phase 2) had CD4 counts above 500 cells/μl. All except one patient
from phase 1 reported being on ART, and the patient who had not yet initiated ART had a
CD4 count of between 100 and 350 cells/ μl. In phase 1, median CD4 counts appeared higher
in women than in men (734 and 478 cells/μl respectively), though only 8 men were present in
the phase 1 sample and this was not a statistically significant difference (Wilcoxon rank sum
test p = 0.17). In phase 2, median CD4 counts were 650 and 677 cells/μl for women and men,
and were not significantly different (p = 0.75). The overall median CD4 count was 595 for
patients in phase 1 and 583 for patients in phase 2. Demographic and clinical details are sum-
marized in Tables 1 and 2.
Accuracy
Mean and median CD4 T cell counts for both venous and capillary blood were compared
between Presto and FACSCount, at the DH and rural lab. When Presto was operated in the
DH (phase 1), higher estimates of both CD4 count and Hgb in venous blood (p<0.001) as well
as in capillary blood (p<0.05) were observed. Bland Altman plots were produced to visualize
absolute mean bias in CD4 count for samples tested by Presto compared to FACSCount. Bias
was 44 (Limits Of Agreement -72, 160) for venous blood, and 74 (LOA -96, 244) for capillary
blood (Table 3, Fig 2A and 2B). The Presto also overestimated Hgb concentration with venous
(p<0.0007) and capillary blood (p<0.0001) in the DH setting when compared to FACSCount
(Table 3, Fig 2C and 2D).
In the rural laboratory setting, the Presto overestimated CD4 counts in both sample types
(Table 3, Fig 2E and 2F). Hemoglobin levels were not significantly different for venous blood
in the rural laboratory setting (p = 0.09), and were significantly lower for capillary blood tested
with the Presto compared to FACSCount (p = 0.01), Table 3.
Spearman’s correlation coefficients demonstrated good correlation for CD4 count (Table 3,
all groups at 0.93 or above). For Hgb, correlation coefficients were lower: 0.73, 0.64, 0.89, and
0.87 for venous blood in the district hospital, capillary blood in district hospital, venous blood
in the rural laboratory, and capillary blood in the rural laboratory, respectively (Table 3).
When comparing results from venous blood to capillary blood in the DH setting, capillary
blood samples gave significantly higher results for both CD4 count and Hgb concentration
(Wilcoxon Signed Rank test p = 0.0017 and<0.0001 respectively). Due to a small number of
Table 1. Demographics: Phase 1 and 2.
Phase 1 Phase 2
Male Female Missing Total Male Female Missing Total
n (%) 8 (12.3%) 57 (87.7%) 0 65 9 (18.8%) 30 (62.5%) 9 (18.8%) 48
Pregnant NA 4 (6.5%) 0 4 N/A N/A 30 30




9 (18.8%) 38 (14.5)
Age Mean (Min- Max) 53 (44–70) 40.3 (24–65) n = 1 (1.5%) 41.9 (24–70) 44.4 (34–58) 41 (19–78) 9 (18.8%) 41.6 (19–78)
On ART at time of study n (X%) 8 (100%) 56 (98.2%) 0 64 (98.4%) N/A N/A 48 (100%) N/A
https://doi.org/10.1371/journal.pone.0212684.t001
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capillary blood samples (n = 10) in the rural laboratory setting, this analysis was restricted to
phase 1 data. While capillary blood gave higher CD4 counts overall, Spearman correlation
coefficients revealed that CD4 count from capillary and venous blood were highly correlated
(Spearman’s Rank Correlation = 0.97, p<0.0001), and correlation between hemoglobin results
from capillary and venous blood was lower but still significant (0.80, p< .0001).
Lastly, rates of misclassification, sensitivity and specificity were analyzed across 3 different
CD4 count thresholds. There was one instance of downward misclassification, when the Presto
classified a sample of venous blood in the rural laboratory as under 350 cells/μl CD4 count,
whereas the FACSCount had classified it as above; all other misclassification was upward
(Table 4). Accordingly, specificity for all categories was 100% apart from venous blood in
phase 2, 350 CD4 count cutoff. Sensitivity was lower, ranging from 50%-100% depending on
the CD4 threshold. Only 2 samples were found to have CD4 counts below 100 and sensitivity
was poor at this cut-off.
Discussion
Advanced HIV disease is defined by the WHO as having a CD4 count of below 200 cells/μL, or
a disease stage of 3 or 4. Despite advancements in access to ART treatment, 30–40% of PLHIV
globally have advanced HIV disease when starting or re-initiating ART [28, 30]. It is critical
that access to CD4 testing be assured in HIV programs, even as viral load testing becomes
more available [12]. POC CD4 testing was shown to double linkage to care rates in a rural Ken-
yan setting [5], and same-day blood draw for CD4 testing was shown to significantly increase
linkage to care and decrease deferment of care in Durban, South Africa [4]. In addition to
impacting linkage to care, assessing the immune status of PLHIV through POC CD4 can iden-
tify advanced HIV disease cases, which should be prioritized for prophylaxis for OIs even if
they are asymptomatic. A randomized controlled trial conducted in 4 sub-Saharan African
countries showed that among patients with CD4 count of below 100 cells/mm3, enhanced anti-
microbial prophylaxis was associated with reduced rates of death and a large proportion (47%)
of patients were either asymptomatic or mildly symptomatic at baseline [31].
Demonstration of device-specific performance can inform the selection of diagnostic tech-
nologies for different settings [6]. We evaluated the performance of the near-patient Presto
device to test its applicability for measuring CD4 count and Hgb concentration in rural West
Africa. Results demonstrated that the Presto consistently over-estimated CD4 count and Hgb
concentration when compared to the FACSCount, and that capillary blood samples gave
higher estimates than venous blood samples. These results are consistent with findings in
other studies. Despite imperfect accuracy, we found that the Presto results for CD4 count and
Hgb were well correlated with reference tests FACSCount and Sysmex, and the Presto was suc-
cessfully operated both in a busy HIV clinic at a district hospital, as well as in a rural laboratory
Table 2. CD4 count distribution by study phase.
Phase 1 Phase 2
CD4 count Median (IQR) (cells/μl), FACSCount 595 (403–847) 583 (280.5–785.3)
CD4� 100 n (%) 2 (3.4%) 2 (4.2%)
CD4 > 100 -� 350 n (%) 8 (14.0%) 10 (20.8%)
CD4 > 350 -� 500 n (%) 13 (22.0%) 9 (18.8%)
CD4 > 500 n (%) 36 (61.0%) 27 (56.2%)
Note: N/A indicates not available. There were no statistically significant differences between males and females or
between the cohort characteristics in phase 1 and phase 2.
https://doi.org/10.1371/journal.pone.0212684.t002
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with limited resources. Sample sizes in low CD4 count ranges were insufficient to establish
whether many cases of advanced disease would be missed as a result of upward misclassifica-
tion. In addition, the small number of patients who presented with low CD4 counts meant that
upward and downward misclassification rates appear disproportionately high for some groups.
For example, one out of two patients with a CD4 count of under 100 was misclassified as being
above 100 by capillary sample in the district hospital.
The Presto presents several major advantages, including speed (it has a total test time of
approximately 25 minutes, only 4 of which take place in the device), throughput (up to 60 sam-
ples in 8 hours), and portability (less than 7 kg and able to be run using battery-power) [12,
13]. On the other hand, it may be important to consider that the Presto gives significant over-
estimations of CD4 count and Hgb, and this may result in cases of advanced diseased or ane-
mia being missed. This is particularly relevant for low-level health facilities without venipunc-
ture, since capillary blood demonstrated the lowest accuracy. These biases should be
considered by providers when interpreting the results of the Presto, particularly when treating
patients with low CD4 count who might be eligible for OI prophylaxis. However, this does not
necessarily reduce its suitability and the convenience of a small, near-patient device such as
Presto may still greatly improve access to CD4 testing in rural areas as long as this bias is
considered.
Like many other West African countries, Ghana has a relatively low HIV burden with an
estimated HIV prevalence of 1.6% among adults aged 15 to 49 in 2016, compared to 7% preva-
lence in Eastern and Southern Africa [32–34]. Control programs in Ghana have worked hard
Table 3. Summary of venous and capillary samples, bias and correlation between Presto and control devices.
Phase 1 (DH Lab) Phase 2 (Rural Lab)
Control Presto-
Venous
p Presto-Capillary p Control Presto-Venous p Presto-Cap p
Number 59 59 57 48 48 10
CD4 Count (cells/μl)








674.8 (87–1525) 939.3 (589–
1480)

























Correlation�� 0.98 <0.0001 0.97 <0.0001 0.97 <0.0001 0.93 0.0001
Hemoglobin Concentration (g/dl)






11.3 (7.0–16.2) 11.4 (8.0–14.2)






























0.74 <0.0001 0.64 <0.0001 0.89 <0.0001 0.88 0.0008
https://doi.org/10.1371/journal.pone.0212684.t003
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to decentralize HIV services so that access to testing and treatment is adequate throughout the
country, even in low-prevalence areas. As Ghana continues to adapt its HIV program and
improve rates of early-diagnosis, it is crucial that CD4+ count testing remain accessible for
newly diagnosed or ART-initiating patients.
Limitations
There are several limitations to this study design. Firstly, the sample size is small, with less than
60 patients in each phase. At the time of this study (2015–2016), it was uncommon for HIV
patients to seek care at low-level health facilities in Ghana, and only 13 patients were recruited
from rural clinics. This resulted in only ten capillary blood samples for this phase of the study,
and these were excluded from some analyses due to the small sample size. Overall, CD4 counts
were relatively high, so it may not be appropriate to extrapolate these results to patients with
low CD4 count.
The technician operating the FACSCount machine at the district hospital (for both phases
of the study) was different from the technician operating the Presto. While neither machine
requires advanced technical skill, and the same training was provided to all technicians, opera-
tor-related differences are possible. Additionally, there are several unknown factors affecting
the second phase of the study (rural laboratory). The exact conditions of storage and transport
Fig 2. Bland-Altman plots comparing absolute CD4 count and hemoglobin measurements from venous or capillary blood samples as measured with
Presto was operated in the district hospital (phase 1) or the rural laboratory (phase 2). Dotted lines indicate the lower and upper limits of agreement and
the solid line indicates the bias.
https://doi.org/10.1371/journal.pone.0212684.g002
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were not systematically documented, and it is possible that the samples were exposed to differ-
ent temperatures and wait times, potentially impacting the accuracy of the Presto in phase 2.
However, as lab testing in resource limited settings often relies on sample transportation to
more centralized sites, this scenario may reflect real-world operation of near-patient CD4 test-
ing devices.
Lastly, this study used BD FACSCount as the reference standard, while BD FACSCalibur is
normally considered the gold standard among these devices. [8]. However, FACSCount is a
widely used device in sub-Saharan Africa and was selected based on its availability, proven
accuracy and acceptability in the local setting.
Conclusion
Reliable CD4 count testing is needed in health facilities to monitor the immune status of
PLHIV, even as access to VL monitoring expands. This study found that the Presto overesti-
mates CD4 count in comparison to FACSCount, which is consistent with other studies com-
paring Presto to FACSCount or FACSCalibur [19–21, 23], though one study in Ethiopia did
find a negative bias of 13.3 cells/μl when comparing Presto to FACSCalibur [16]. Overall, the
accuracy of the Presto machine must be considered, since over-estimation of CD4 count could
result in missing cases of advanced HIV disease, and overestimation of Hgb concentration
could result in missed cases of anemia. Future work conducted on much larger datasets could
determine whether the bias observed is systematic or random error, and explore possible
adjustments to Presto in order to control for overestimation. Despite current limitations how-
ever, the Presto can still enable access to CD4 testing, and was successfully operated in a very
rural lab setting. It could also be particularly valuable in Preventing Mother To Child Trans-
mission (PMTCT) programs where hemoglobin measurements are clinically important, but
further research is needed into the accuracy of hemoglobin measurements from Presto when
operated in this context.
Supporting information
S1 Table. BD Presto performance data. This table includes the study ID numbers for all sam-
ples analyzed, and the CD4 count and hemoglobin results from BD Presto, BD FACSCount
(CD4 Count) and the Sysmex KX– 21N.
(XLSX)
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